Strategies that delay or prevent the timely availability of affordable generic drugs in the United States.

TitleStrategies that delay or prevent the timely availability of affordable generic drugs in the United States.
Publication TypeJournal Article
Year of Publication2016
AuthorsJones GH, Carrier MA, Silver RT, Kantarjian H
JournalBlood
Volume127
Issue11
Pagination1398-402
Date Published2016 Mar 17
ISSN1528-0020
KeywordsAntitrust Laws, Drug Approval, Drug Costs, Drug Industry, Drug Substitution, Drugs, Generic, Economic Competition, Global Health, Insurance, Pharmaceutical Services, Lobbying, Patents as Topic, Prescription Fees, Therapeutic Equivalency, United States, United States Food and Drug Administration
Abstract

High cancer drug prices are influenced by the availability of generic cancer drugs in a timely manner. Several strategies have been used to delay the availability of affordable generic drugs into the United States and world markets. These include reverse payment or pay-for-delay patent settlements, authorized generics, product hopping, lobbying against cross-border drug importation, buying out the competition, and others. In this forum, we detail these strategies and how they can be prevented.

DOI10.1182/blood-2015-11-680058
Alternate JournalBlood
PubMed ID26817958
PubMed Central IDPMC4915805

Richard T. Silver MD Myeloproliferative Neoplasms Center 525 East 70th St., Starr Pavillion, 3rd Floor New York, NY 10021 SilverMPNCenter@med.cornell.edu